The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program
Open accessAbstract
BACKGROUND: Osteosarcoma, which is the most common primary bone tumor, occurs most frequently in adolescents, but there is a second incidence peak among individuals aged >60 years. Most osteosarcoma epidemiology studies have been embedded in large analyses of all bone tumors or focused on cases occurring in adolescence. Detailed descriptions of osteosarcoma incidence and survival with direct comparisons among patients of all ages and ethnicities are not available. METHODS: Frequency, incidence, and survival rates for 3482 patients with osteosarcoma from the National Cancer Institute's population‐based Surveillance, Epidemiology, and End Results (SEER) Program between 1973 and 2004 were investigated by age (ages 0‐24 years, 25‐59 years, and 60 to ≥85 years), race, sex, pathology subtype, stage, and anatomic site. RESULTS: There were large differences in incidence and survival rates by age. There was a high percentage of osteosarcoma with Paget disease and osteosarcoma as a second or later cancer among the elderly. There was a high percentage of osteosarcoma among patients with Paget disease and osteosarcoma as a second or later cancer among the elderly. Tumor site differences among age groups were noted. Survival rates varied by anatomic site and disease stage and did not improve significantly from 1984 to 2004. CONCLUSIONS: This comprehensive, population‐based description of osteosarcoma, identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups, and quantified the impact of osteosarcoma in patients with Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications in understanding osteosarcoma biology and epidemiology. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Osteosarcoma is the most common primary malignant tumour of the bone.”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“higher rates of osteosarcoma have been observed in African American children and young adults in the USA than in white individuals 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence is bimodal, peaking at 18 and 60 years of age”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Osteosarcoma incidence has a bimodal age distribution with a primary peak in adolescents and young adults and a second, smaller peak in the seventh and eighth decade of life 1”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“In the USA, osteosarcoma accounts for <1% of all new cancer diagnoses with ~1,000 new cases diagnosed per year, half of these cases occurring in children and adolescents 1 .”
From Osteosarcoma (2022) · cites this paper as [1]
In the citing paper
“Some studies suggested that the histological subtype of osteosarcoma can influence the degree of necrosis, with chondroblastic and telangiectatic subtypes having less necrosis but those differences have not translated into improvement in survival 1,118 .”
From Osteosarcoma (2022) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
(1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,933
The international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Trends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2007) · Cancer · doi:10.1002/cncr.23169 · Cited by 644
Bleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma
Damron, T. A., Ward, W. G., & Stewart, A. K. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/blo.0b013e318059b8c9 · Cited by 530
Osteogenic sarcoma. A study of six hundred cases.
Dahlin, D. C., & Coventry, M. B. (1967) · PubMed · Cited by 475
Bone Tumors: General Aspects and Data on 8,542 Cases
Spjut, H. J. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61914-4 · Cited by 455
Dahlin, D. C., & Coventry, M. B. (1967) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196749010-00008 · Cited by 453
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Research works printed but not linked: 12
- 10.1002/1097-0142(19950101)75:1 <203::AID-CNCR2820751308>3.0.CO;2-V · DOI
- Dorfman HA, 1997, Bone Tumors
- Murray RO, 1975, A Textbook of Radiology, 109
- Hanson MR, 1982, Epidemiology of Cancer in the Young
- 10.1002/1097-0142(19860715)58:2 <598::AID-CNCR2820581332>3.0.CO;2-C · DOI
- Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 2007, SEER Registries: Surveillance Research Program, National Cancer Institute
- Surveillance Research Program, 2007, National Cancer Institute SEER*Stat Software, version 6.3.6
- Day JC, 1996, Population Projections of the United States by Age, Sex, Race and Hispanic Origin, 1995 to 2050, US Bureau of the Census, Current Population Reports, P25‐1130
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 13 Regs Limited‐Use, November 2006 Submission (1992‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 9 Regs Limited‐Use, November 2006 Submission (1973‐2004)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2007, SEER*Stat Database: Incidence‐SEER 17 Regs Limited‐Use, November 2006 Submission (1973‐2004 varying)‐Linked to County Attributes‐Total US, 1969‐2004 Counties
- Aegerter E, 1975, Orthopedic Disease
Cited by
Sorted by citations
Items 801–900 of 1,002
Pettke, A., Hotfilder, M., Clemens, D., Klco‐Brosius, S., Schaefer, C., Potratz, J. C., & Dirksen, U. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000418 · Cited by 21
miR-365 functions as a tumor suppressor by directly targeting CYR61 in osteosarcoma
Xu, Y., Chu, H., Zhou, Y., Wang, J., Dong, C., & Yin, R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.086 · Cited by 21
Kitamoto, K., Miura, Y., Karnan, S., Ota, A., Konishi, H., Hosokawa, Y., & Sato, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.8291 · Cited by 21
Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis
Zhang, Y., He, Z., Duan, Y., Wang, C., Kamar, S., Shi, X., Yang, J., Yang, J., Zhao, N., Han, L., et al. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.04.001 · Cited by 21
TRIM44, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma
Wang, H., Fang, Z., Zhang, G., & Ma, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s163163 · Cited by 21
MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma
Gong, N., & Gong, M. (2018) · Medicine · doi:10.1097/md.0000000000011100 · Cited by 21
Lawrenz, J. M., Curtis, G. L., Styron, J. F., George, J., Anderson, P. M., Zahler, S. G., Shepard, D. R., Rubin, B. P., Nystrom, L. M., & Mesko, N. W. (2018) · Sarcoma · doi:10.1155/2018/1728302 · Cited by 21
Huang, Q., Li, X., Huang, Z., Yu, F., Wang, X., Wang, S., He, Z., & Lin, J. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00637-w · Cited by 21
Bouaoud, J., Beinse, G., Epaillard, N., Sahli-Amor, M., Bidault, F., Brochériou, I., Herve, G., Spano, J., Janot, F., Boudou, P., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.011 · Cited by 21
Yang, J., Lin, R.-C., Hsieh, Y., Wu, H., Li, G.-C., Lin, Y., Yang, S., & Lu, K. (2019) · Molecules · doi:10.3390/molecules24183280 · Cited by 21
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice
Raghubir, M., Rahman, C., Fang, J., Matsui, H., & Mahajan, S. S. (2019) · Oncology Reports · doi:10.3892/or.2019.7420 · Cited by 22
Rao, S. R., Somarelli, J. A., Altunel, E., Selmic, L. E., Byrum, M., Sheth, M. U., Cheng, S., Ware, K. E., Kim, S. Y., Prinz, J. A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00117 · Cited by 21
p53 Is Not Required for High CIN to Induce Tumor Suppression
Hrycyniak, L., Wan, J., Ryan, S. D., Kaur, C., Sullivan, R., Roopra, A., & Weaver, B. A. A. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0488 · Cited by 21
Yuan, X., Zhang, P., Yu, T., Huang, H., Zhang, L., Yang, C., Tan, T., Yang, S., Luo, X., & Luo, J. (2020) · PubMed Central · Cited by 21
Yi, X., Cao, Z., Yuan, Y., Li, W., Cui, X., Chen, Z., Hu, X., & Yu, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.028 · Cited by 21
Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
Tang, L., Niu, X., Wang, Z., Cai, Q., Tu, C., Fan, Z., & Yao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811687 · Cited by 21
Lu, K., Chen, P., Lue, K., Lai, M., Lin, M.-S., Hsieh, Y., & Chu, S. (2014) · Nutrition and Cancer · doi:10.1080/01635581.2014.894100 · Cited by 21
SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013
Redondo, A., Cruz, J. J., Pousa, A. L., & Barón, F. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1087-0 · Cited by 21
Prion proteins (PRNP and PRND) are over‐expressed in osteosarcoma
Sollazzo, V., Galasso, M., Volinia, S., & Carinci, F. (2011) · Journal of Orthopaedic Research® · doi:10.1002/jor.22034 · Cited by 21
Primary diaphyseal osteosarcoma in long bones: Imaging features and tumor characteristics
Wang, C., Yin, Q., Liao, J.-S., Lou, J., Ding, X., Zhu, Y., & Chen, K. (2012) · European Journal of Radiology · doi:10.1016/j.ejrad.2012.03.021 · Cited by 21
High level of αB-crystallin contributes to the progression of osteosarcoma
Shi, Q., Luo, J. F., Wu, K., Yin, M., Gu, Y.-R., & Cheng, X. (2016) · Oncotarget · doi:10.18632/oncotarget.6928 · Cited by 21
Qi, B., Yu, T., Wang, C., Wang, T., Yao, J., Zhang, X., Deng, P., Xia, Y., JUNGER, W. G., & Sun, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0437-5 · Cited by 21
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis
Smeester, B. A., Slipek, N. J., Pomeroy, E. J., Bomberger, H. E., Shamsan, G. A., Peterson, J. J., Crosby, M. R., Draper, G. M., Becklin, K. L., Rahrmann, E. P., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1041-x · Cited by 21
Retracted: Ribosomal Protein S15A Augments Human Osteosarcoma Cell Proliferation In Vitro
Zhang, C., Zhang, T., Song, E., Himaya, S. W. A., Chen, X., & Zheng, L. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1698 · Cited by 21
RetractedExploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis
Huang, Y., Cao, D., Zhang, M., Yang, Y., Niu, G., Tang, L., Shen, Z., Zhang, Z., Bai, Y., Min, D., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00949-3 · Cited by 20
Boyland, R. F., Amin, S., Shostrom, V., Zheng, C., Allison, J., & Lin, C. H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13496-3 · Cited by 20
Murine models of osteosarcoma: A piece of the translational puzzle
Walia, M., Castillo‐Tandazo, W., Mutsaers, A. J., Martin, T. J., & Walkley, C. R. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26601 · Cited by 20
Ren, J., Yang, M., Xu, F., & Chen, J. (2019) · Europe PMC (PubMed Central) · Cited by 20
miR-96-5p is the tumor suppressor in osteosarcoma via targeting SYK
Wang, T., Xu, Y. J., Liu, X., Zeng, Y., & Liu, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.07.069 · Cited by 20
Alsaeed, M. A., Ebrahimi, S., Alalikhan, A., Hashemi, S. F., & Hashemy, S. I. (2022) · BioMed Research International · doi:10.1155/2022/8082608 · Cited by 20
Yuan, B., Shi, K., Zha, J., Cai, Y., Gu, Y., Huang, K., Yue, W., Zhai, Q., Ding, N., Ren, W., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05545-7 · Cited by 21
Tissue microRNA-126 expression level predicts outcome in human osteosarcoma
Liu, W., Zhao, Z., Shi, L., & Yuan, W. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0329-6 · Cited by 20
A role for maintenance therapy in managing sarcoma
Ray-Coquard, I. L., & Cesne, A. L. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.003 · Cited by 20
Osteosarcoma: Time to move on?
Bielack, S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.009 · Cited by 20
Ding, Y., Wang, Y., Chen, J., Hu, Y., Cao, Z., Ren, P., & Zhang, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1404-9 · Cited by 20
Detection and Evaluation of Normal and Malignant Cells Using Laser-Induced Fluorescence Spectroscopy
Khosroshahi, M. E., & Rahmani, M. (2011) · Journal of Fluorescence · doi:10.1007/s10895-011-0958-4 · Cited by 20
The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data
Li, H., Min, D., Zhao, H., Wang, Z., Qi, W., Zheng, S., Tang, L., He, A., Sun, Y., Yao, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064513 · Cited by 20
Targeted therapies in bone sarcomas: current approach and future directions
Yarber, J. L., & Agulnik, M. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.577064 · Cited by 20
Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A
Ni, Z., Shang, X., Wang, Y. F., Sun, Y., & Fu, D. J. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15027807 · Cited by 20
White, B., Rossi, V. M., & Baugher, P. J. (2016) · Photomedicine and Laser Surgery · doi:10.1089/pho.2016.4091 · Cited by 20
miR-22 promotes apoptosis of osteosarcoma cells via inducing cell cycle arrest
Gai, P., Sun, H., Wang, G., Xu, Q., Qi, X., Zhang, Z., & Jiang, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.5674 · Cited by 20
Wang, Y., Wang, S., Liu, J., Lu, Y., & Li, D. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.05.007 · Cited by 20
Prognostic significance of the expression of HER family members in primary osteosarcoma
Wang, S., Zhong, G., Wang, X., Yu, F., Weng, D., Wang, X., & Lin, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8931 · Cited by 20
Lima, F. T., Seba, V., SILVA, G. H. D. O., Torrezan, G. S., Polaquini, C. R., Pinhanelli, V. C., Baek, S. J., Fachin, A. L., Regasini, L. O., & Marins, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071909 · Cited by 20
Systematic meta-analysis of genetic variants associated with osteosarcoma susceptibility
Wang, X., & Liu, Z. (2018) · Medicine · doi:10.1097/md.0000000000012525 · Cited by 20
Zhuo, F., Zhang, C., Zhang, H., Xia, Y., Xue, G., Yang, L., & Kong, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27991 · Cited by 20
Zheng, L., Hu, N., & Zhou, X. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.12.031 · Cited by 20
Nani, A., Belarbi, M., Murtaza, B., Benammar, C., Merghoub, T., Rialland, M., Khan, N. A., & Hichami, A. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.01.042 · Cited by 20
Zhang, Y., Zhao, H., Wu, X., Jiang, D., Huang, L., & Li, L. (2019) · Journal of Cancer · doi:10.7150/jca.28480 · Cited by 21
Zaikova, O., Hall, K. S., Styring, E., Eriksson, M., Trovik, C. S., Bergh, P., Bjerkehagen, B., Skorpil, M., Weedon‐Fekjær, H., & Bauer, H. C. F. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.24074 · Cited by 20
Geng, S., Sun, B., Lu, R., & Wang, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0934 · Cited by 20
Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas?
Nandra, R. S., Parry, M., Forsberg, J. A., & Grimer, R. J. (2017) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-017-5346-1 · Cited by 20
Dai, G., Yu, L., Yang, J. M., Xia, K., Zhang, Z., Liu, G., Gao, T., & Guo, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19554 · Cited by 20
Lan, M., Zhu, X.-P., Cao, Z.-Y., Liu, J.-M., Lin, Q., & Liu, Z.-L. (2018) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.07.010 · Cited by 19
Schulte, B., Mohindra, N., Milhem, M., Attia, S., Robinson, S., Monga, V., Hirbe, A. C., Oppelt, P., Charlson, J., Helenowski, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01448-0 · Cited by 19
Davis, L. E., Jeng, S., Svalina, M. N., Huang, E., Pittsenbarger, J., Cantor, E. L., Berlow, N., Séguin, B., Mansoor, A., McWeeney, S. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19532 · Cited by 19
Chen, Z., Liu, Z., Yang, Y., Zhu, Z., Liang, R., Huang, B., Wu, D., Yang, L., Lü, H., Jin, D.-D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24247 · Cited by 19
Yang, Y. A., Basu, S., Mirabello, L. J., Spector, L. G., & Zhang, L. (2018) · Cancer Informatics · doi:10.1177/1176935118775103 · Cited by 19
Self-citationOsteosarcoma after the age of fifty: A clinicopathological study
Tempelaere, C., Biau, D. J., Babinet, A., & Anract, P. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.04.010 · Cited by 19
Long-Noncoding RNA PCAT6 Aggravates Osteosarcoma Tumourigenesis via the MiR-143-3p/ZEB1 Axis
Wu, K., Feng, Q., Li, L., Xiong, Y., Liu, S., Liu, J., & Wu, Q. H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s258415 · Cited by 19
RetractedJin, W., Gu, C., Zhou, L., Yang, X., Gui, M., Zhang, J., Chen, J., Dong, X., Yuan, Q., & Shan, L. (2020) · Oncology Reports · doi:10.3892/or.2020.7801 · Cited by 19
Spalek, M. J., Poleszczuk, J., Czarnecka, A. M., Dudzisz‐Śledź, M., Napieralska, A., Matysiakiewicz, J., Chojnacka, M., Raciborska, A., Sztuder, A., Maciejczyk, A., et al. (2021) · Cells · doi:10.3390/cells10020366 · Cited by 19
Yu, B., Liu, L., Cai, F., Peng, Y., Tang, X., Zeng, D., Li, T., Zhang, F., Liang, Y., Yuan, X., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02443-y · Cited by 19
Zhang, T., Li, S., Li, J., Yin, F., Hua, Y., Wang, Z., Wang, H., Zuo, D., Xu, J., & Cai, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113323 · Cited by 19
Molecular imaging of sarcomas with FDG PET
Mendoza, H. G., Nosov, A., & Pandit-Taskar, N. D. (2022) · Skeletal Radiology · doi:10.1007/s00256-022-04182-7 · Cited by 19
Multifunctional inorganic biomaterials: New weapons targeting osteosarcoma
Wang, D., Peng, Y., Li, Y., Kpegah, J. K. S. K., & Chen, S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1105540 · Cited by 19
Withers, S. S., Moeller, C. E., Quick, C. N., Liu, C., Baham, S. M., Looper, J., Subramanian, R., & Kousoulas, K. G. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284645 · Cited by 22
Spectral computed tomography-guided radiotherapy of osteosarcoma utilizing BiOI nanosheets
Fu, Z., Li, K., Wang, H., Li, Y., Zhang, J., Zhou, J., Hu, J., Xie, D., & Ni, D. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.026 · Cited by 19
KLF transcription factors in bone diseases
Wang, H., Han, J., Gorbachev, D. O., Ning, K., & Zhang, X. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18278 · Cited by 19
Zhang, Y., Chen, Y., Mou, H., Huang, Q., Jian, C., Tao, Y., Tan, F., & Ou, Y. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103328 · Cited by 19
P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.
Bu, J., Li, H., Liu, L., Ouyang, Y., Guo, H., Li, X., & Xiao, T. (2014) · PubMed Central · Cited by 19
Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression
Yu, L., Liu, S., Guo, W., ZHANG, B., Liang, Y., & Feng, Q. (2012) · Oncology Reports · doi:10.3892/or.2012.2032 · Cited by 19
Choeyprasert, W., Pakakasama, S., Sirachainan, N., Songdej, D., Chuansumrit, A., Anurathapan, U., Hongeng, S., & Nartthanarung, A. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9823 · Cited by 19
He, J., ZHANG, P., Li, Q., Zhou, D., & Liu, P. (2015) · Oncology Letters · doi:10.3892/ol.2015.3907 · Cited by 19
Classical osteosarcoma in children and adolescents
Рогожин, Д. В., Булычева, И. В., Коновалов, Д. М., Гаврилович, Т. А., Roshchin, V. Y., Эктова, А. П., Богородицкий, Ю. С., Strykov, V. A., Казакова, А. Н., Olshanskaya, Y. V., et al. (2015) · Russian Journal of Archive of Pathology · doi:10.17116/patol201577568-74 · Cited by 19
Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population.
Ru, J., Cong, Y., Kang, W., Yu, L., Guo, T., & Zhao, J. (2015) · PubMed Central · Cited by 19
Kim, J., & Gilbert, J. L. (2018) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34109 · Cited by 19
Wu, D., Zhang, H., Ji, F., & Ding, W. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.10.012 · Cited by 19
Saikosaponin D inhibits proliferation of human osteosarcoma cells via the p53 signaling pathway
Zhao, L., Li, J., Sun, Z., Sun, C., Yu, Z., & Guo, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6969 · Cited by 19
Long noncoding RNA DNAJC3‐AS1 promotes osteosarcoma progression via its sense‐cognate gene DNAJC3
Liang, R., Liu, Z., Chen, Z., Yang, Y., Li, Y., Cui, Z., Chen, A., Long, Z., Chen, J., Lü, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1955 · Cited by 19
A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma
Wagner, F., Holzapfel, B. M., Martine, L. C., McGovern, J., Lahr, C. A., Boxberg, M., Prodinger, P. M., Grässel, S., Loessner, D., & Hutmacher, D. W. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.02.051 · Cited by 19
Liu, Y., Sun, X., Huo, C., Sun, C., & Zhu, J. (2019) · Medical Science Monitor · doi:10.12659/msm.912272 · Cited by 19
Zhao, X., Li, J., & Yu, D. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4333 · Cited by 19
RetractedLi, W., Zhang, X., Xi, X., Li, Y., Quan, H., Liu, S., Wu, L., Wu, P., Lan, W., Shao, Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3066 · Cited by 19
Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma
Liang, X., Wang, X., He, Y., Wu, Y., Zhong, L., Liu, W., Liao, D., & Kang, T. (2020) · Theranostics · doi:10.7150/thno.46082 · Cited by 19
Zhong, J., Hu, Y., Si, L., Geng, J., Xing, Y., Jiao, Q., Zhang, H., & Yao, W. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100305 · Cited by 19
Alternative splicing of leptin receptor overlapping transcript in osteosarcoma
Rothzerg, E., Ho, X. D., Xu, J., Wood, D., Märtson, A., Maasalu, K., & Kõks, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220949139 · Cited by 19
Tal, A. L., Doshi, H., Parkar, F., Abraham, T., Love, C., Ye, K. Q., Yang, R. R., Hoang, B. H., Loeb, D. M., Chou, A. J., et al. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001917 · Cited by 19
Kamalapathy, P. N., Ramkumar, D. B., Karhade, A. V., Kelly, S., Raskin, K. A., Schwab, J. H., & Lozano‐Calderón, S. A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26398 · Cited by 19
Survival from teenage and young adult cancer in Northern England, 1968–2008
Basta, N. O., James, P. W., Gómez‐Pozo, B., Craft, A. W., Norman, P. D., & McNally, R. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.24939 · Cited by 19
Choeyprasert, W., Natesirinilkul, R., Charoenkwan, P., & Sittipreechacharn, S. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.2.1101 · Cited by 19
Shu, J., Li, L., Sarver, A. E., Pope, E. A., Varshney, J., Thayanithy, V., Spector, L. G., Largaespada, D. A., Steer, C. J., & Subramanian, S. (2016) · Oncotarget · doi:10.18632/oncotarget.6965 · Cited by 19
Interleukin-22 Promotes Osteosarcoma Cell Proliferation and Invasion via STAT3 Activation
Li, P., Shi, X., Xu, Y., Zhong, B., Lu, Y., & Sun, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.910962 · Cited by 19
Yu, W., Tang, L., Feng, L., Yang, Y., & Shen, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00655 · Cited by 19
GDF15 promotes osteosarcoma cell migration and invasion by regulating the TGF‑β signaling pathway
Chen, G., Wang, M., & Liu, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10664 · Cited by 19
FKBP14 overexpression contributes to osteosarcoma carcinogenesis and indicates poor survival outcome
Huang, Z., Li, J., Du, S., Tang, Y., Huang, L., Xiao, L., & Tong, P. (2016) · Oncotarget · doi:10.18632/oncotarget.9524 · Cited by 20
RetractedBringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers
Cahill, J. A., Smith, L. A., Gottipati, S., Torabi, T. S., & Graim, K. S. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-102423-111936 · Cited by 18
lncRNA GAS8-AS1 downregulates lncRNA UCA1 to inhibit osteosarcoma cell migration and invasion
Zha, Z., Han, Q., Liu, W., & Huo, S. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-1550-x · Cited by 18
Liu, J., Lian, T., Chen, H., Wang, X., Quan, X., Deng, Y., Yao, J., Lu, M., Ye, Q., Feng, Q., et al. (2021) · BioMed Research International · doi:10.1155/2021/6674471 · Cited by 18
HO-3867 Induces Apoptosis via the JNK Signaling Pathway in Human Osteosarcoma Cells
Lu, P. W., Chou, C., Yang, J., Hsieh, Y., Tsai, M., Lu, K., & Yang, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061257 · Cited by 18
Metadata
- Authors
- Mirabello, L., Troisi, R. J., & Savage, S. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Savage, Sharon A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-02-05
- Volume
- 115
- Issue
- 7
- Pages
- 1531-1543
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC2813207
- OpenAlex
- W1988325237
- Cited by
- 2,199
- References
- 52
- Citations by year
- 2026: 114 · 2025: 138 · 2024: 166 · 2023: 167 · 2022: 161 · 2021: 194 · 2020: 201 · 2019: 162 · 2018: 172 · 2017: 142 · 2016: 151 · 2015: 129 · 2014: 106 · 2013: 72 · 2012: 52
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01CP010142)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- osteosarcoma, incidence, survival rate, age differences, Paget disease, secondary malignancies, elderly patients, disease stage, SEER, bone tumors, mortality trends
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Bone Neoplasms, Child, Child, Preschool, Ethnicity, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Osteosarcoma, Sex Factors, Survival Rate, SEER Program
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
